Clinical Trials Arena on MSN

ImmunityBio’s Anktiva shows success as combo treatment in NSCLC

Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...
The American Journal of Managed Care

Exploring CAR T-Cell Therapy Efficacy in Earlier Vs Later Lines of Therapy

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
Medscape

Third- and Further-line Therapy in Advanced Non-small-cell Lung Cancer Patients

The most widely studied targeted therapies for the third- and further-line treatment of NSCLC are EGFR inhibitors: gefitinib, erlotinib, cetuximab and afatinib (Table 3). The most important predictive ...
The American Journal of Managed Care

Navigating First-Line Therapy Guidelines and Treatment Considerations in High-Risk Cytogenetics

Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...
Healio

Combination extends survival vs. standard first-line therapy for advanced lung cancer

Please provide your email address to receive an email when new articles are posted on . The combination of amivantamab-vmjw and lazertinib extended OS by more than 1 year. Previously reported results ...
Medscape

First-Line Urate-Lowering Therapy for Gout: Xanthine Oxidase Inhibitor or Mechanism-Based Approach?

For gout, xanthine oxidase (XO) inhibitors are the choice for first-line urate-lowering therapy (ULT) according to the 2020 American College of Rheumatology Guideline for the Management of Gout, which ...